Skip to main content
ARVINAS, INC. logo

ARVINAS, INC. — Investor Relations & Filings

Ticker · ARVN ISIN · US04335A1051 US Professional, scientific and technical activities
Open in API
Filings indexed 550 across all filing types
Latest filing 2026-06-02 Regulatory Filings
Country US United States of America
Listing US ARVN

About ARVINAS, INC.

https://www.arvinas.com/

Arvinas, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics based on targeted protein degradation. The company is a leader in this field, utilizing its proprietary PROTAC® (PROteolysis TArgeting Chimera) platform to create a new class of drugs. This technology is designed to harness the body's own cellular machinery to selectively remove disease-causing proteins. Arvinas is advancing a pipeline of investigational therapies targeting debilitating and life-threatening diseases, with a primary focus on oncology and neuroscience. The company was the first in its field to advance an investigational drug through a pivotal trial and submit a New Drug Application to U.S. regulators.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 92% confidence The document is a U.S. SEC Form 8-K (“Current Report”) disclosing a Regulation FD presentation and other corporate events. It is a miscellaneous regulatory filing, not a full financial report, call transcript, or other specific category. Hence it falls under general Regulatory Filings (RNS).
2026-06-02 English
8-K - ARVINAS, INC. (0001655759) (Filer)
Earnings Release Classification · 85% confidence The document is a Form 8-K “Current Report” filed under Item 2.02 to announce the quarter‐ended March 31, 2026 financial results via a press release (Exhibit 99.1). This is the standard filing mechanism for an earnings release. Therefore, it should be classified as an Earnings Release (ER). Q1 2026
2026-05-12 English
8-K - ARVINAS, INC. (0001655759) (Filer)
Regulatory Filings Classification · 15% confidence The document is a Current Report on Form 8-K filed under the Securities Exchange Act of 1934 reporting entry into a license agreement and furnishing a press release, which constitutes a general regulatory announcement rather than a full financial report, earnings release, management discussion, or any other specific category. It does not contain substantial financial statements or detailed operational analysis, nor is it merely an announcement of another report. Therefore, it falls under the general Regulatory Filings category.
2026-05-12 English
10-Q - ARVINAS, INC. (0001655759) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-11 English
8-K - ARVINAS, INC. (0001655759) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events or corporate changes that shareholders should know about. The content focuses on the FDA approval of a drug (VEPPANU), milestone payments related to this approval, and other related corporate updates. It includes a press release as an exhibit and forward-looking statements. There are no financial statements or detailed financial data presented, nor is this an annual or quarterly report. The document is not a proxy, earnings release, or management discussion. It is a regulatory announcement of a significant event, typical of a Regulatory Filing (RNS). The document length (7184 characters) and content confirm it is not a mere announcement of a report but a substantive current report filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-05-01 English
ARS - ARVINAS, INC. (0001655759) (Filer)
Annual Report
2026-04-29 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.